Radiation Oncology (May 2025)

Deep learning-powered radiotherapy dose prediction: clinical insights from 622 patients across multiple sites tumor at a single institution

  • Zhen Hou,
  • Lang Qin,
  • Jiabing Gu,
  • Zidong Liu,
  • Juan Liu,
  • Yuan Zhang,
  • Shanbao Gao,
  • Jian Zhu,
  • Shuangshuang Li

DOI
https://doi.org/10.1186/s13014-025-02634-7
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 18

Abstract

Read online

Abstract Purpose Accurate pre-treatment dose prediction is essential for efficient radiotherapy planning. Although deep learning models have advanced automated dose distribution, comprehensive multi-tumor analyses remain scarce. This study assesses deep learning models for dose prediction across diverse tumor types, combining objective and subjective evaluation methods. Methods and materials We included 622 patients with planning data across various tumor sites: nasopharyngeal carcinoma (n = 29), esophageal carcinoma (n = 82), left-sided breast carcinoma (n = 107), right-sided breast carcinoma (n = 95), cervical carcinoma treated with radical radiotherapy (n = 84), postoperative cervical carcinoma (n = 122), and rectal carcinoma (n = 103). Dose predictions were generated using U-Net, Flex-Net, and Highres-Net models, with data split into training (60%), validation (20%), and testing (20%) sets. Quantitative comparisons used normalized dose difference (NDD) and dose-volume histogram (DVH) metrics, and qualitative assessments by radiation oncologists were performed on the testing set. Results Predicted and clinical doses correlated well, with NDD values under 3% for tumor targets in nasopharyngeal, breast, and postoperative cervical cancer. Qualitative assessments revealed that U-Net, Flex-Net, and Highres-Net achieved the highest accuracy in cervical radical, breast/rectal/postoperative cervical, and nasopharyngeal/esophageal cancers, respectively. Among the test cases (n = 123), 53.7% were deemed clinically acceptable and 32.5% required minor adjustments. The “Best Selection” approach, combining strengths of all three models, raised clinical acceptance to 62.6%. Conclusion This study demonstrates that automated dose prediction can provide a robust starting point for rapid plan generation. Leveraging model-specific strengths through the “Best Selection” approach enhances prediction accuracy and shows potential to improve clinical efficiency across multiple tumor types.

Keywords